Acadia Hit By Two Surprise Disappointments With Nuplazid
No Future For MDD, No Priority Review For Dementia
Executive Summary
A couple of unexpected events for pimavanserin mean that Acadia will drop its development for major depressive disorder and have to wait a little longer to hear if it can launch the product for dementia-related psychosis, a large potential indication.
You may also be interested in...
Acadia Claims Success For Nuplazid In A Broader Psychosis Indication
The company expects to file pimavanserin for the treatment of dementia-related psychosis in 2020, based on the results of a single positive Phase III trial.
Pimavanserin Fails In ENHANCE But Other CNS Uses Targeted
Acadia halts evaluation of pimavanserin as a schizophrenia adjunct but continues study of effect on negative symptoms and in other CNS conditions.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.